HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LMAT
LeMaitre Vascular, Inc.
LMAT's fundamentals are strong and it looks cheap: trading at 28x earnings, below its usual 43x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LMAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
LMAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LMAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $77.65 | — |
| Current | 28x | $77.65 | — |
| Cheap | 35x | $97.74 | +26% |
| Fair | 43x | $118 | +52% |
| Expensive | 52x | $143 | +85% |
Historical ranges are pointers, not guarantees.
LMAT's PE is in its cheap range at 28x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LMAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
LMAT has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LMAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.08 | +12% |
| Q3 2026 | $2.76 | +19% |
| Q2 2026 | $2.86 | +40% |
| Q1 2026 | $2.72 | +38% |
| Q4 2025 | $2.52 | +31% |
| Q3 2025 | $2.31 | +26% |
| Q2 2025 | $2.05 | +23% |
| Q1 2025 | $1.97 | +30% |
| Q4 2024 | $1.93 | +44% |
LMAT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LMAT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
LMAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $68M | +11% |
| Q2 2026 | $70.4M | +9.6% |
| Q1 2026 | $66.6M | +11% |
| Q4 2025 | $64.5M | +16% |
| Q3 2025 | $61M | +11% |
| Q2 2025 | $64.2M | +15% |
| Q1 2025 | $59.9M | +12% |
| Q4 2024 | $55.7M | +14% |
LMAT's revenue has grown year over year every quarter since late 2020: $68M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -7.2 points |
| Q2 2026 | 29% | +3.9 points |
| Q1 2026 | 27% | +5.6 points |
| Q4 2025 | 29% | +6.1 points |
| Q3 2025 | 33% | +9.3 points |
| Q2 2025 | 25% | -0.6 points |
| Q1 2025 | 21% | -1.1 points |
| Q4 2024 | 23% | +2.2 points |
LMAT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LMAT on cash flow, with more consistent year-over-year improvement.
LMAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $19.7M | -26% |
| Q2 2026 | $13.7M | -28% |
| Q1 2026 | $12.3M | +61% |
| Q4 2025 | $21.4M | +63% |
| Q3 2025 | $26.5M | +111% |
| Q2 2025 | $18.9M | +145% |
| Q1 2025 | $7.7M | +107% |
| Q4 2024 | $13.1M | +39% |
LMAT's free cash flow has been positive every quarter for seven years: $67M over the past year, up 1.2% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LMAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LMAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6% | -1.5M shares |
| 1 year | -5.4% | -1.3M shares |
| 3 years | +2.6% | +590K shares |
| 5 years | +5.2% | +1.1M shares |
| Available history | +14% | +2.7M shares |
LMAT has 23M diluted shares, down 5.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $17,000 |
| Q1 2026 | $460,000 |
| Q4 2025 | $1.2M |
| Q3 2025 | — |
| Q2 2025 | $4,000 |
| Q1 2025 | $601,000 |
| Q4 2024 | $1.4M |
LMAT has spent almost nothing on buybacks in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LMAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
LMAT has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LMAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 7.0 | Oversold |
LMAT's weekly RSI is 37 (neutral) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LMAT PE vs Healthcare Sector
| Metric | LMAT | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 8.8% above |
| PE % | 3 | 29 | 26 pts below |
LMAT is trading at 28x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LMAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 3.8% below |
| 20 week MA | $85.8 | 9.5% below |
| 50 week MA | $92.4 | 16% below |
| 100 week MA | $90.2 | 14% below |
| 200 week MA | $79.0 | 1.7% below |
LMAT is in a downtrend: it's below all five of its weekly moving averages, and 1.7% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LMAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.2 | $38.4 | +6.1% |
| 2021 | $38.4 | $51.5 | +34% |
| 2022 | $51.5 | $45.8 | -11% |
| 2023 | $45.8 | $56.8 | +24% |
| 2024 | $56.8 | $92.8 | +64% |
| 2025 | $92.8 | $83.8 | -9.8% |
| 2026 YTD | $83.8 | $77.7 | -7.3% |
LMAT has the edge over HIMS on returns for 2026, with the stronger performance.